Dermatology-specific and all-cause 30-day and calendar-year readmissions and costs for dermatologic diseases from 2010 to 2014 - 15/08/19
Abstract |
Background |
Readmissions for skin disease, particularly for the same diagnosis and over time, have not been well studied.
Objective |
To characterize hospital readmissions for skin disease.
Methods |
A cross-sectional observational study examined the Nationwide Readmissions Database from 2010 to 2014, a national sample of hospital discharges in the United States.
Results |
Of the patients in 3,602,599 dermatologic hospitalizations from 2010 to 2014, 9.8% were readmitted for any cause, 3.3% were admitted for the same diagnosis within 30 days, and 7.8% were readmitted for the same diagnosis within the calendar year (CY). The cost of all CY same-cause readmissions was $508 million per year. Mycosis fungoides had the highest 30-day all-cause readmission rate (32%), vascular hamartomas and dermatomyositis had the highest 30-day same-cause readmission rates (21% and 18%, respectively), and dermatomyositis and systemic lupus erythematosus had the highest CY same-cause readmission rates (31% and 24%, respectively). Readmission rates stayed stable from 2010 to 2014. Readmission for the same diagnosis was strongly associated with Medicaid and morbid obesity.
Limitations |
This study is a broad description of hospitalizations for skin disease. Conclusions for individual diseases are not intended.
Conclusion |
The rates and costs of readmissions for skin diseases remained high from 2010 to 2014. This study identifies diseases associated with high risk of hospital readmission, but disease-specific studies are needed. The diseases and risk factors presented should guide additional studies focused on strategies to reduce readmissions in specific skin diseases.
Le texte complet de cet article est disponible en PDF.Key words : cost of care, dermatology hospitalizations, dermatology readmissions, epidemiology, hospital readmissions, inpatient dermatology, Nationwide Readmissions Database
Abbreviations used : CY, DRG, ICD-9, NRD
Plan
Funding sources: Supported in part through the National Institutes of Health/National Cancer Institute Cancer Center (Support Grant P30 CA008748). |
|
Conflicts of Interest: None disclosed |
|
Reprints not available from the authors. |
Vol 81 - N° 3
P. 740-748 - septembre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?